Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ. Talaris’ proprietary technology allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs) safely from unmatched and unrelated donors, without the toxicity and risks of a traditional bone marrow tr...
Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ. Talaris’ proprietary technology allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs) safely from unmatched and unrelated donors, without the toxicity and risks of a traditional bone marrow transplant.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.